Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen

AIDS

Volumn 14, Issue 1, 2000, Pages 11-21

  Valdez, Hernan ^a,j   Smith, Kimberly Y ^b   Landay, Alan ^b   Connick, Elizabeth ^c   Kuritzkes, Daniel R ^c   Kessler, Harold ^b   Fox, Lawrence ^d   Spritzler, John ^e   Roe, Joana ^f   Lederman, Miriam B ^g   Lederman, Howard M ^g   Evans, Thomas G ^h   Heath Chiozzi, Margo ⁱ   Lederman, Michael M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f AIDS Clinical Trials Group Operations Center   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ROCHESTER   (United States)

ⁱ ABBOTT LABORATORIES   (United States)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

more..

Author keywords

Antibodies; Antiretroviral therapy; Delayed type hypersensitivity responses; Hepatitis A; Immune activation; Immunization; Keyhole limpet hemocyanin; Lymphocyte proliferative responses; Pathogenesis; Protease inhibitors; Tetanus toxoid

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNEACTIVATOR; KEYHOLE LIMPET HEMOCYANIN; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; TETANUS ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG; VIRUS ANTIGEN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; EDEMA; ERYTHEMA; FEMALE; HEPATITIS A; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TETANUS; VIRUS LOAD; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEMOCYANIN; HEPATITIS A VACCINES; HIV-1; HUMANS; HYPERSENSITIVITY, DELAYED; INJECTIONS, INTRADERMAL; LAMIVUDINE; MALE; MIDDLE AGED; RITONAVIR; T-LYMPHOCYTES; TETANUS TOXOID; THYMUS GLAND; VACCINATION; VIRAL HEPATITIS VACCINES; ZIDOVUDINE;

EID: 0033985563     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001070-00002     Document Type: Article

References (57)

1. 1. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981, 305:1425-1431.
2. 2. Mildvan D, Mathur U, Enlow RW, et al. Opportunistic infections and immune deficiency in homosexual men. Ann Intern Med 1982,96:700-704.
3. 3. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA. CD8 naive T-cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995, 95:2061-2066.
4. 4. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989, 84:1892-1899.
5. 5. Birx DL, Brundage J, Larson K, et al. The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. Military Medical Consortium for Applied Retroviral Research. J Acquir Immune Defic Syndr 1993, 6:1248-1257.
6. 6. Dolan MJ, Clerici M, Blatt SP, et al. In vitro T-cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995, 172:79-87.
7. 7. Valentine FT, Paolino A, Saito A, Holzman RS. Lymphocyte-proliferative responses to HIV antigens as a potential measure of immunological reconstitution in HIV disease. AIDS Res Hum Retrovir 1998, 14 Suppl 2:5161-5166.
8. 8. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983, 309:453-458.
9. 9. Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988, 109:101-105.
10. 10. Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus- infected and -uninfected homosexual men. J Infect Dis 1997, 176:1064-1067.
11. 11. Ochs HD, Junker AK, Collier AC, Virant FS, Handsfield HH, Wedgwood RJ. Abnormal antibody responses in patients with persistent generalized lymphadenopathy. J Clin Immunol 1988, 8:57-63.
12. 12. Kroon FP, Van Dissel JT, de Jong JC, Van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 1994, 8:469-476.
13. 13. Janoff EN, Hardy WD, Smith PD, Wahl SM. Humoral recall responses in HIV infection. Levels, specificity, and affinity of antigen-specific IgG. J Immunol 1991, 147:2130-2135.
14. 14. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998, 351:543-549.
15. 15. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
16. 16. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
17. 17. Connick E, Lederman M, Kotzin B, et al. and the ACTC 315 Protocol. Immunologic Effects of 48 Weeks of AZT/3TC/RITONAVIR. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 1998 [Late Breaker LB14].
18. 18. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998, 351:1682-1686.
19. 19. Sokal JE. Editorial: Measurement of delayed skin-test responses. N Engl J Med 1975, 293:501-502.
20. 20. ACTG. AIDS Clinical Trials Group Consensus Methodologies: NIH, 1997. http://aactg.s-3.com.
21. 21. Lee DC, Lederman HM. Anti-tetanus toxoid antibodies in intravenous gamma globulin: an alternative to tetanus immune globulin. J Infect Dis 1992, 166:642-645.
22. 22. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998, 178:70-79.
23. 23. McCune JM, Loftus R, Schmidt DK, et al. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest 1998, 101:2301-2308.
24. 24. Smith K, Valdez H, Landay A, et al. Correlations Between Immunologic Indices and Thymic Mass in HIV-infected Patients following 48 weeks of Zidovudine, Lamivudine, and Ritonavir (ZLR). 12th World AIDS Conference. Geneva, Switzerland, June 1998 [abstract 21129].
25. 25. Lehmann. Nonparametrics: Statistical Methods Based on Ranks. San Francisco: Holden-Day, 1975.
26. 26. Conover W. Practical Nonparametric Statistics. New York: Wiley, 1980.
27. 27. Zar J. Biostatistical Analysis. Englewood Cliffs, NJ: Prentice-Hall, Inc., 1984.
28. 28. Breslow NE, Day NE. Statistical Methods in Cancer Research, Volume 1: World Health Organization International Agency for Research on Cancer, The World Health Organization, The analysis of case-control studies. 1980:192.
29. 29. Scheibel I. The uses and results of active tetanus immunization. Bull. World Health Org. 1955, 13:381-394.
30. 30. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
31. 31. Curtis JE, Hersh EM, Harris JE, McBride C, Freireich EJ. The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clin Exp Immunol 1970, 6:473-491.
32. 32. Opravil M, Fierz W, Matter L, Blaser J, Luthy R. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol 1991, 84:185-189.
33. 33. Teeuwsen VJ, Logtenberg T, Siebelink KH, et al. Analysis of the antigen-and mitogen-induced differentiation of B lymphocytes from asymptomatic human immunodeficiency virus-seropositive male homosexuals. Discrepancy between T cell-dependent and T cell-independent activation. J Immunol 1987, 139: 2929-2935.
34. 34. Talesnik E, Vial PA, Labarca J, Mendez C, Soza X. Time course of antibody response to tetanus toxoid and pneumococcal capsular polysaccharides in patients infected with HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:471-477.
35. 35. Bruguera M, Cremades M, Salinas R, Costa J, Grau M, Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol 1992, 14:27-30.
36. 36. Hess G, Clemens R, Bienzle U, Schonfeld C, Schunck B, Bock HL. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 1995, 46:40-42.
37. 37. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985, 313:79-84.
38. 38. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 1994, 6:414-419.
39. 39. Haffar OK, Smithgall MD, Wong JG, Bradshaw J, Linsley PS. Human immunodeficiency virus type 1 infection of CD4+ T cells down- regulates the expression of CD28: effect on T cell activation and cytokine production. Clin Immunol Immunopathol 1995, 77:262-270.
40. 40. Brinchmann JE, Dobloug JH, Heger BH, Haaheim LL, Sannes M, Egeland T. Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: functional and clinical correlations. J Infect Dis 1994, 169:730-738.
41. 41. Kammerer R, Iten A, Frei PC, Burgisser P. Expansion of T cells negative for CD28 expression in HIV infection. Relation to activation markers and cell adhesion molecules, and correlation with prognostic markers. Med Microbiol Immunol (Berl) 1996, 185:19-25.
42. 42. Roos MT, Miedema F, Meinesz AP, et al. Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression. Clin Exp Immunol 1996, 105:409-415.
43. 43. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993, 262:1011-1018.
44. 44. Purvis SF, Georges DL, Williams TM, Lederman MM. Suppression of interleukin-2 and interleukin-2 receptor expression in Jurkat cells stably expressing the human immunodeficiency virus Tat protein. Cell Immunol 1992, 144:32-42.
45. 45. McCormick-Davis C, Zhao LJ, Mukherjee S, et al. Chronology of genetic changes in the vpu, env, and Nef genes of chimeric simian-human immunodeficiency virus (strain HXB2) during acquisition of virulence for pig-tailed macaques. Virology 1998, 248:275-283.
46. 46. Gurley RJ, Ikeuchi K, Byrn RA, Anderson K, Groopman JE. CD4+ lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci U S A 1989, 86:1993-1997.
47. 47. Levitz SM. Improvement in CD4+ cell counts despite persistently detectable HIV load [letter]. N Engl J Med 1998, 338:1074-1075.
48. 48. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study [letter]. Lancet 1998, 351:723-724.
49. 49. Fahey JL, Taylor JM, Manna B, et al. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS 1998, 12:1581-1590.
50. 50. Dezube BJ, Lederman MM, Chapman B, et al. The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels. J Infect Dis 1997, 176:807-810.
51. 51. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993, 6:904-912.
52. 52. Giorgi JV, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Detels R. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998, 12:1833-1844.
53. 53. Girndt M, Kohler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Buschenfelde KH, Fleischer B. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995, 47:559-565.
54. 54. Lees O, Ramzaoui S, Gilbert D, et al. The impaired in vitro production of interleukin-2 in HIV infection is negatively correlated to the number of circulating CD4+DR+ T cells and is reversed by allowing T cells to rest in culture: arguments for in vivo CD4+ T cell activation. Clin Immunol Immunopathol 1993, 67:185-191.
55. 55. Patki A, Lederman M, Purvis S, et al. HIV-1 infection perturbs DNA content of peripheral blood mononuclear cells: effects of antiviral therapy. AIDS 1999, 13:1177-1185.
56. 56. Pawelec GP, Rehbein A, Schaudt K, Busch FW. IL-4-responsive human helper T cell clones are resistant to growth inhibition by tumor necrosis factor-alpha. J Immunol 1989, 143:902-906.
57. 57. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol 1988, 141:2629-2634.